Plain-English translation of NCT06399640 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of two medications— and —given together to treat people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to earlier treatments. Researchers want to find the right dose of that works safely and effectively when combined with , and then measure how well this treatment combination helps patients.
People whose blood cancers return or no longer respond to standard treatments have very limited options. This medication combination targets cancer cells in new ways, and researchers believe pairing these two drugs together might help patients who have exhausted other treatment choices.
You likely qualify if…
You likely don't qualify if…
You would take by mouth once daily, 5 days per week for 14, 21, or 28 days per cycle, along with once daily for the first 14 days of each 28-day cycle. Throughout the study, you would have regular blood tests and bone marrow biopsies to check how you're responding. After you finish treatment, you would return for follow-up visits every 3 months for up to 2 years.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States